



FOR IMMEDIATE RELEASE

Christine McCarty
312 596 1617
cmccarty@ziegler.com

ZIEGLER ADVISES PATHOLOGISTS BIO-MEDICAL LABORATORIES ON ITS ACQUISITION BY PATHGROUP

CHICAGO, IL – JUNE 5, 2019 – Ziegler, a specialty investment bank, is pleased to announce its role as the exclusive financial advisor to [Pathologists Bio-Medical Laboratories \(PBM\)](#) on its recent acquisition by [PathGroup](#).

Headquartered in Lewisville (Dallas), Texas, PBM is a preeminent anatomic pathology platform that provides services to more than one dozen hospitals and surgery centers in the Dallas-Fort Worth and broader Texas geographies through more than 40 board-certified and subspecialty pathologists. The platform's subspecialty expertise includes Bone and Soft Tissue Pathology, Breast Pathology, Cytopathology, Forensic Pathology, Gastrointestinal Pathology, Hematopathology, Liver Pathology, Molecular Pathology, Nephropathology, Neuropathology, Pulmonary Pathology, and Urologic Pathology, among others.

PBM's CAP- and CLIA-accredited laboratory in Lewisville will serve as the foundation for PathGroup's accelerated expansion into the North Texas market, and PBM's broad subspecialty expertise will complement PathGroup's existing national pathology footprint. The combined company will include more than 120 pathologists, representing every subspecialty and creating one of the most comprehensive pathology networks in the country.

"PBM and PathGroup have similar histories of providing high-quality pathology services to patients, physicians and health systems," said Peter A. Dysert, M.D., President of PBM. "Our like-minded cultures of physician leadership and private ownership will allow us to focus on what is best for the clients and patients we serve. We look forward to working with PathGroup and continuing to exceed the expectations of our hospitals and physician clients."

[Grant Chamberlain](#), Managing Director in Ziegler's Healthcare Corporate Finance Practice stated, "This transaction concludes a decade long journey that we have had assisting PBM and Dr. Dysert through multiple transactions to keep PBM as one of the most respected, innovative and coveted AP practice in the country. We couldn't be more pleased with the ideal cultural fit with PathGroup."

[Patrick Walsh](#), Director in Ziegler's Healthcare Corporate Finance Practice added, "PBM is a great addition to the PathGroup family – a pathology practice that has kept its focus on patient care and consultative relationships with other physicians throughout its 55-plus year history; and PathGroup is the perfect partner for PBM as each continues to seek growth and navigate the constantly-changing role of laboratory services in the U.S. healthcare system."

Ziegler's Corporate Finance team is focused on delivering best-in-class advisory and financing solutions for companies and organizations across the healthcare industry. In our core practice areas of healthcare services, information technology, hospitals and senior living, Ziegler is one of the most active M&A firms offering innovative sell-side, buy-side, recapitalization/restructuring, equity private placement and strategic partnering services.

For more information about Ziegler, please visit us at www.ziegler.com.

About Ziegler:

Ziegler is a privately held, national boutique investment bank, capital markets and proprietary investments firm. We have a unique focus on the healthcare, senior living and education sectors, as well as general municipal and structured finance. Headquartered in Chicago with regional and branch offices throughout the U.S., Ziegler provides its clients with capital raising, strategic advisory, fixed income sales & trading and research. To learn more, visit www.ziegler.com.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client's experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.

###